Cosmetic

Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology

Retrieved on: 
Monday, June 5, 2023
Science, Other Science, Biotechnology, Research, Oncology, Health, Genetics, Clinical Trials, Investigator's brochure, Neoplasm, National Comprehensive Cancer Network, Cosmetic, NCCN, Guideline, Patient, Risk, Lymph node, Recurrence, Metastasis, Disease, Medical imaging

“The algorithm that we developed is not meant to challenge these established guidelines.

Key Points: 
  • “The algorithm that we developed is not meant to challenge these established guidelines.
  • In the study, three private-practice Mohs surgeons, who routinely use the test to risk-stratify their high-risk cSCC patients, merged their management approaches for three real-world, high-risk cSCC patients into a singular algorithm that provides a framework for incorporating each of the test’s three potential results into current NCCN guidelines.
  • In all three cases presented in the study, use of the algorithm incorporating DecisionDx-SCC test results led to no evidence of disease recurrence or metastasis post-treatment, based on the timing described in the study.
  • The study findings support the use of DecisionDx-SCC test results within established guidelines to enable personalized, risk-aligned management of high-risk cSCC patients and the allocation of healthcare resources to patients at the highest risk of a poor outcome.

AAMI, BSI Join Forces to Publish Guidance on Artificial Intelligence

Retrieved on: 
Wednesday, May 31, 2023
International Electrotechnical Commission, BSI, Regulation of tobacco by the U.S. Food and Drug Administration, AAMI, American National Standards Institute, SC, ISO, Internet Technical Committee, Risk management, Intelligence, British Standards, Cosmetic, Standard, Federal Food, Drug, and Cosmetic Act, Patient, Machine learning, Artificiality, Artificial intelligence, IEC, CR, Philips, AI, Health, International Organization (journal), TC, Food, Safety, International Organization for Standardization, Software, Medical device, Agency

Arlington, VA, May 31, 2023 (GLOBE NEWSWIRE) -- AAMI and the British Standards Institute (BSI) have jointly published guidance documents on performing risk management for machine learning (ML) or artificial intelligence (AI) incorporating medical devices.

Key Points: 
  • Arlington, VA, May 31, 2023 (GLOBE NEWSWIRE) -- AAMI and the British Standards Institute (BSI) have jointly published guidance documents on performing risk management for machine learning (ML) or artificial intelligence (AI) incorporating medical devices.
  • AAMI Technical Information Report (TIR)34971:2023, Application of ISO 14971 to machine learning in artificial intelligence – Guide , derives from a 2022 AAMI consensus report (CR).
  • The British Standard is designated as BS/AAMI 34971:2023, Application of ISO 14971 to machine learning in artificial intelligence — Guide.
  • “The key difference about the TIR is that we’re doing it jointly with BSI,” said Hae Choe, principal director of standards at AAMI.

ZIVO’s GRAS Designation Reaffirmed for Proprietary Algal Biomass Product as a Human Food Ingredient

Retrieved on: 
Tuesday, May 30, 2023
Agriculture, Biotechnology, Natural Resources, Pharmaceutical, Health, Food, Beverage, Retail, Other Health, GRAS, FDA, Drink, Biomass, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Federal Food, Drug, and Cosmetic Act, Cosmetic, Safety, Dietary supplement

GRAS is a designation created by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act that determines if a food ingredient or additive has adequate evidence of safety to be consumed under the conditions of intended use.

Key Points: 
  • GRAS is a designation created by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act that determines if a food ingredient or additive has adequate evidence of safety to be consumed under the conditions of intended use.
  • GRAS status conveys to manufacturers and marketers that they are able to safely integrate ZIVO’s algal biomass ingredient into food processing lines and products, and to include its nutritional information on product labels.
  • The present GRAS review is based on commercial-scale cultivation processes and parameters, which better represent ZIVO’s planned commercial product.
  • The analysis concludes that ZIVO’s algal biomass, as cultivated for commercial use, is exempt from the premarket approval requirements of the FDA.

QVC's Beauty with Benefits Event Empowers Cancer Survivors with Every Purchase

Retrieved on: 
Monday, May 1, 2023
Honey, Workforce, Survivor, London, QVC, CEW, Benefit, Butter, Workplace, Cosmetic Executive Women, Cosmetic, WEN, Cosmetics, Philosophy, Estate (law), Patient, Beauty salon, Beauty, Cancer, Career

WEST CHESTER, Pa., May 1, 2023 /PRNewswire/ -- QVC, a world leader in live video commerce ("vCommerce") and Cosmetic Executive Women (CEW) are proud to announce the return of the highly anticipated Beauty with Benefits multiplatform shopping event, supporting Cancer and Careers. Over the past decade, Beauty with Benefits has raised over $16 million for Cancer and Careers. In its 11th year, the event will offer a video shopping experience for beauty enthusiasts while raising funds to help people with cancer thrive in their workplace. To increase awareness for this year's campaign, celebrity makeup artist and founder of Mally Beauty, Mally Roncal, will lend her vibrant spirit and passion as the spokesperson for the event.

Key Points: 
  • Over the past decade, Beauty with Benefits has raised over $16 million for Cancer and Careers.
  • Over the past decade, Beauty with Benefits has raised over $16 million for Cancer and Careers.
  • A minimum of 70 percent of the purchase price* of donated merchandise benefits Cancer and Careers.
  • "We are so proud of the impact Beauty with Benefits has had on the Cancer and Careers organization," said Anna Baker, Vice President, General Merchandise Manager, Beauty, QVC.

Turn Biotechnologies Shows Promise of Epigenetic Reprogramming to Rejuvenate Skin at SEASON Aesthetic Conference

Retrieved on: 
Monday, May 1, 2023
Maintenance, Bio, Stem cell, Biotechnology, Research, Cosmetic, Messenger, ERA, Patient, Extracellular matrix, Faculty, ECM, Epigenetics, George Washington University, Conference, Skin, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
  • The data discussed at SEASON Aesthetic Conference showed that Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology reprograms cells within the extracellular matrix (ECM), resulting in a broad panel of changes related to improved skin quality and structure.
  • Research demonstrates that Turn Bio's cellular data in-vitro has translated to the tissue level ex-vivo.
  • Dr. Hsia, who has worked in biotechnology for nearly 20 years, was gratified by the experience of presenting to SEASON attendees.

Acclaimed Dallas, TX, Plastic Surgeon, Dr. David Azouz Recognized as a 2023 Top Patient Rated Plastic Surgeon by Find Local Doctors

Retrieved on: 
Thursday, April 27, 2023
Mayo, Male, Face, Doctor, Quality of life, Breast, Cosmetic, Female, Suite, Patient, Physician, Lip, Plastic surgery, Dentistry, DALLAS

DALLAS, April 27, 2023 /PRNewswire-PRWeb/ -- At Azouz Plastic and Cosmetic Surgery, the team specializes in aesthetic surgery of the face, breast and body, providing the latest surgical techniques and innovative non-surgical treatments at the state-of-the-art clinic. Dr. David Azouz's positive reviews through multiple online sources and five-star ratings have helped him earn this distinguished award from Find Local Doctors. Find Local Doctors is a user-friendly online directory, that helps consumers connect with skilled physicians in their area who are well-known for their expertise. Patients have praised Azouz Plastic and Cosmetic Surgery for the attention to detail and meticulous artistry they provide when performing cosmetic surgery and treatments, delivering natural-looking results.

Key Points: 
  • Azouz Plastic and Cosmetic Surgery in Dallas, TX, offers the talent of two board-certified plastic surgeons, Dr. David Azouz and Dr. Solomon Azouz.
  • More About Azouz Plastic and Cosmetic Surgery:
    Azouz Plastic and Cosmetic Surgery proudly serves patients in the Dallas/Ft.
  • Azouz Plastic and Cosmetic Surgery includes two board-certified plastic surgeons, recognized as the best in their field in Dallas, Texas.
  • For more information or to schedule a consultation, please contact Azouz Cosmetic and Plastic Surgery by calling (972) 702-8888 or visiting the website at http://www.drazouz.com
    Dr. Sol Azouz, Azouz Plastic and Cosmetic Surgery, (972)702-8888, [email protected]

Cosmetic Executive Women (CEW) Hosts Annual Women's Leadership Awards

Retrieved on: 
Wednesday, April 26, 2023
Partnership, Olaplex, Female, CEW, Beauty, HSN, Cosmetic Executive Women, Skin, Woman, Multimedia, Global Leadership Awards, Cosmetic, Rare Beauty, Hair, Sustainability, Kargo, Tarte, Entrepreneurship, Enneagram of Personality, Dior, Ghana UK-Based Achievement Awards, Fairchild Group, SVP, Dyson, Ulta Beauty, Catalysis, Nursing, Beauty salon, Cosmetics, Unilever

NEW YORK, April 26, 2023 /PRNewswire/ -- Cosmetic Executive Women (CEW) celebrated women and achievement Tuesday at the 2023 Women's Leadership Awards – a program that embodies CEW's mission to motivate, elevate, and advance female leaders who are shaping the beauty industry today.

Key Points: 
  • NEW YORK, April 26, 2023 /PRNewswire/ -- Cosmetic Executive Women (CEW) celebrated women and achievement Tuesday at the 2023 Women's Leadership Awards – a program that embodies CEW's mission to motivate, elevate, and advance female leaders who are shaping the beauty industry today.
  • "I am absolutely thrilled to continue to honor these amazing, accomplished women through the CEW Women's Leadership Awards," said Carlotta Jacobson, CEW President.
  • "These awards reinforce the importance of recognition and opportunity for female leadership.
  • Without women, this business would not exist, and it is now more important than ever to showcase the valuable contributions of female leaders."

Strict Regulations for Single-Use Plastics Will Drive the Growth of Returnable Packaging Market Size to USD 170.93 billion by 2029 at 6.2% CAGR | Exactitude Consultancy

Retrieved on: 
Thursday, March 30, 2023
IBC, Biopolymer, Food, Starch, Fruit, Perception, Consumer, Automotive industry, Transport, Cosmetic, USD, Polyhydroxyalkanoates, Final good, Personal care, Reusable Industrial Packaging Association, Food packaging, Wood, Composition, The Return of Depression Economics and the Crisis of 2008, TPP, PHA, Agricultural and Processed Food Products Export Development Authority, National Plant, Flower and Fruit Guild, Agriculture, PBAT, PLA, Growth, Industrial, Glass, PBS, Speciality chemicals, Video game, Pet industry, Marketing, Textile

PUNE, India, March 30, 2023 /PRNewswire/ -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Returnable Packaging Market.

Key Points: 
  • Germany's Returnable Packaging market size was valued at USD 10.64 billion in 2021 and is expected to reach USD 15.36 billion by 2029, at a CAGR of 4.7% from 2022 to 2029.
  • India's Returnable Packaging market size was valued at USD 12.39 billion in 2021 and is expected to reach USD 18.3 billion by 2029, at a CAGR of 5% from 2022 to 2029.
  • In 2022, the pallets segment dominated the market with the largest market share of 57.0% and market revenue of 33.84 billion.
  • In 2022, the pallets segment dominated the market with the largest market share of 57.0% and market revenue of 33.84 billion.

Strict Regulations for Single-Use Plastics Will Drive the Growth of Returnable Packaging Market Size to USD 170.93 billion by 2029 at 6.2% CAGR | Exactitude Consultancy

Retrieved on: 
Thursday, March 30, 2023
IBC, Biopolymer, Food, Starch, Fruit, Perception, Consumer, Automotive industry, Transport, Cosmetic, USD, Polyhydroxyalkanoates, Final good, Personal care, Reusable Industrial Packaging Association, Food packaging, Wood, Composition, The Return of Depression Economics and the Crisis of 2008, TPP, PHA, Agricultural and Processed Food Products Export Development Authority, National Plant, Flower and Fruit Guild, Agriculture, PBAT, PLA, Growth, Industrial, Glass, PBS, Speciality chemicals, Video game, Pet industry, Marketing, Textile

PUNE, India, March 30, 2023 /PRNewswire/ -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Returnable Packaging Market.

Key Points: 
  • Germany's Returnable Packaging market size was valued at USD 10.64 billion in 2021 and is expected to reach USD 15.36 billion by 2029, at a CAGR of 4.7% from 2022 to 2029.
  • India's Returnable Packaging market size was valued at USD 12.39 billion in 2021 and is expected to reach USD 18.3 billion by 2029, at a CAGR of 5% from 2022 to 2029.
  • In 2022, the pallets segment dominated the market with the largest market share of 57.0% and market revenue of 33.84 billion.
  • In 2022, the pallets segment dominated the market with the largest market share of 57.0% and market revenue of 33.84 billion.

STATEMENT OF DANCO LABORATORIES REGARDING MIFEPREX®

Retrieved on: 
Friday, March 17, 2023
Bleeding, IUD, Misoprostol, Food and Drug Administration, Prescription, Federal Food, Drug, and Cosmetic Act, Angioedema, Hypovolemic shock, Cosmetic, Patient, Rash, Syncope, Fungal infection, Essential medicines, REMS, Pregnancy, Allergy, Diarrhea, Internal bleeding, Pharmacy, Gestational age, Weakness, Prostaglandin, Sepsis, Vomiting, Leukocytosis, Administration, Death, Anaphylaxis, Hearing, FDA, Headache, Woman, Exercise, Health care, Fever, World Health Organization, Danco, Abdominal pain, Danco Laboratories, Tachycardia, Dizziness, Anemia, Genetically modified bacteria, Medication, Vaginal bleeding, Reading, Nausea, Hematocrit, Food, Full, Pharmaceutical industry, Birth control, Vaccine, Dentistry, Nursing, Mifepristone, Infection

The hearing laid bare both the unprecedented nature of the plaintiffs' legal theory and the speculative nature of their factual allegations.

Key Points: 
  • The hearing laid bare both the unprecedented nature of the plaintiffs' legal theory and the speculative nature of their factual allegations.
  • This too would upend the pharmaceutical industry and has no basis in (and in fact contradicts) the statute, FDA's regulations or case law.
  • The plaintiffs ultimately were forced to admit that they could point to no precedent consistent with their view of the federal statutes at issue.
  • Danco joined this lawsuit in order to ensure that the FDA approval of Mifeprex® remains in force and people continue to have access to this safe and effective product.